Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study

CompletedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Chemotherapy-Related Cognitive ImpairmentHealthy
Interventions
OTHER

Usability study

"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."

Trial Locations (2)

08902

Bright Cloud Int'l Corp, North Brunswick

New Jersey Bioscience Center, North Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers, The State University of New Jersey

OTHER

lead

Bright Cloud International Corp

INDUSTRY

NCT04839588 - Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study | Biotech Hunter | Biotech Hunter